SPAS(SH:603168) Shang Hai Zheng Quan Bao·2025-03-17 18:52Core Viewpoint - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Tafluprost Eye Drops, which is expected to enhance the company's product portfolio and optimize its product layout [1][3]. Drug Registration Details - Drug Name: Tafluprost Eye Drops - Dosage Form: Ophthalmic preparation - Specification: 0.0015% (0.3ml: 4.5μg) - Registration Category: Class 4 chemical drug - License Holder: Zhejiang Shapuaisi Pharmaceutical Co., Ltd. - Production Company: Zhejiang Shapuaisi Pharmaceutical Co., Ltd. - Approval Conclusion: The drug meets the registration requirements as per the relevant laws and regulations [1]. R&D Investment - The cumulative R&D investment for this drug amounts to approximately 6.461 million RMB [2]. Impact on the Company - The approval of Tafluprost Eye Drops will further enrich the company's product categories, benefiting its product layout optimization [3]. - The future production and sales of the drug are subject to various factors such as pharmaceutical industry policies, bidding procurement, and market environment changes, which introduce uncertainties regarding the impact on the company's performance [3].